A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
R-Pharm
R-Pharm
National Cancer Institute (NCI)
Servier
AbbVie
Astellas Pharma Inc
Amgen
Amgen
SWOG Cancer Research Network
Eastern Cooperative Oncology Group
Stanford University
Gruppo Oncologico del Nord-Ovest
Vanderbilt-Ingram Cancer Center
Amgen
Stanford University
Vanderbilt-Ingram Cancer Center
National Cancer Institute, Naples
UNICANCER
Erasca, Inc.
Northwestern University
Australasian Gastro-Intestinal Trials Group
Erasca, Inc.
IFOM ETS - The AIRC Institute of Molecular Oncology
Federation Francophone de Cancerologie Digestive
Blokhin's Russian Cancer Research Center
Al-Azhar University
National Cancer Institute, Naples
Matteo's Friends
City Clinical Oncology Hospital No 1
The Netherlands Cancer Institute